RU2003133451A - Фармацевтические композици для перорального и местного применения - Google Patents
Фармацевтические композици для перорального и местного применения Download PDFInfo
- Publication number
- RU2003133451A RU2003133451A RU2003133451/15A RU2003133451A RU2003133451A RU 2003133451 A RU2003133451 A RU 2003133451A RU 2003133451/15 A RU2003133451/15 A RU 2003133451/15A RU 2003133451 A RU2003133451 A RU 2003133451A RU 2003133451 A RU2003133451 A RU 2003133451A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- esters
- component
- chor
- preceding paragraphs
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 239000000203 mixture Substances 0.000 claims 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims 5
- 229930195729 fatty acid Natural products 0.000 claims 5
- 239000000194 fatty acid Substances 0.000 claims 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical group CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 5
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical group CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 4
- 150000004665 fatty acids Chemical class 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 239000005642 Oleic acid Substances 0.000 claims 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical group CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000003349 gelling agent Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 229940070765 laurate Drugs 0.000 claims 2
- 229940049918 linoleate Drugs 0.000 claims 2
- 229940105132 myristate Drugs 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- 229940049964 oleate Drugs 0.000 claims 2
- 229920000223 polyglycerol Polymers 0.000 claims 2
- 229940114926 stearate Drugs 0.000 claims 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical group CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims 2
- ZNVBEWJRWHNZMK-SYOLRUPNSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,2 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O ZNVBEWJRWHNZMK-SYOLRUPNSA-N 0.000 claims 1
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 claims 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical group CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 108010036941 Cyclosporins Proteins 0.000 claims 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 claims 1
- 235000004443 Ricinus communis Nutrition 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 108010019594 cyclosporin D Proteins 0.000 claims 1
- 108010019249 cyclosporin G Proteins 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- -1 fatty acid esters Chemical class 0.000 claims 1
- 239000007863 gel particle Substances 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 229960003511 macrogol Drugs 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
Claims (13)
1. Фармацевтическая композиция для перорального или местного применения, содержащая
а) 0,1-30,0% одного или нескольких гидрофобных активных ингредиентов;
b) 0,1-60,0% одного или нескольких желатинирующих веществ, выбранных из полиглицериновых эфиров жирных кислот формулы (1)
CH2OR-CHOR-CH2O-[CH2CHOR-CH2O-]nCH2-CHOR-CH2OR (1),
в которой n равно целому числу от 4 до 13, а R представляет собой H или COR’, где R’ представляет собой С8-22 насыщенный, ненасыщенный или гидроксилированный алкил и где, по крайней мере, одна группа R не является водородом, обладающих значением HLB, не меньшим 10;
с) 0,1-60,0% одного или нескольких гель-образующих веществ, выбранных из полиглицериновых эфиров жирных кислот и/или ненасыщенных жирных кислот формулы (2)
CH2OR-CHOR-CH2O-[CH2CHOR-CH2O]nCH2-CHOR-CH2OR (2),
в которой n равно целому числу от 0 до 10, а R представляет собой H или COR”, где R” представляет собой С8-22 насыщенный, ненасыщенный или гидроксилированный алкил и где, по крайней мере, одна группа R не является водородом, обладающих значением HLB, не меньшим 9;
d) 1,0-60% одного или нескольких ко-желатинирующих веществ, выбранных из макроголглицериновых эфиров триглицеридов, частичных глицеридов или жирных кислот или макроголовых эфиров жирных кислот, причем среднее количество прореагировавшего в ходе синтеза указанных веществ этиленоксида составляет 50-150 моль, и одновременно отношение между компонентами b) и d) составляет от 0,1:1 до 10:1;
е) 5,0-30% этанола,
где вышеприведенные проценты составляют в целом 100%,
и где при разведении водой композиция образует дисперсию полиморфных гелевых частиц, имеющих размер от 0,2 до 500 мкм.
2. Композиция по п.1, в которой соотношение а:с и/или а:е составляет от 0,001:1 до 10:1.
3. Композиция по п.1 или 2, в которой R’ представляет собой С16-18 насыщенный или ненасыщенный алкил.
4. Композиция по п.3, в которой R выбран из группы, состоящей из олеата, линолеата, стеарата, линолата, миристата, лаурата и их смесей.
5. Композиция по п.4, в которой компонент b) выбран из полиглицерил-10-эфиров жирных кислот.
6. Композиция по п.5, в которой R” представляет собой С16-18 насыщенный или ненасыщенный алкил.
7. Композиция по п.6, в которой R выбран из группы, состоящей из олеата, линолеата, стеарата, изостеарата, линолата, миристата, лаурата и их смесей.
8. Композиция по любому из предшествующих пунктов, в которой компонент с) выбран из полиглицерил-3-эфиров олеиновой кислоты.
9. Композиция по любому из предшествующих пунктов, в которой компонент d) представляет собой макроголгликоль гидрированное касторовое масло.
10. Композиция по любому из предшествующих пунктов, в которой компонент b) выбран из полиглицерил-10-эфиров олеиновой кислоты, компонент с) выбран из полиглицерил-3-эфиров олеиновой кислоты, и компонент d) представляет собой макрогол(1760)глицерин гидрированное касторовое масло.
11. Композиция по любому из предшествующих пунктов, в которой компонент а) выбран из циклоспоринов, особенно, циклоспорина А, циклоспорина D или циклоспорина G, в которой соотношение компонентов а:с+е составляет 1,001:1 до 1,5:1.
12. Композиция по любому из предшествующих пунктов, дополнительно содержащая наполнители, модифицирующие физическую, химическую стабильность, устойчивость к микробам, органолептические свойства или свойства физической обработки композиции.
13. Фармацевтическая дозированная форма, содержащая желатиновую капсулу, включающую в себя композицию, охарактеризованную в любом из предшествующих пунктов.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9919288.2 | 1999-08-17 | ||
| GB9919288A GB2355656B (en) | 1999-08-17 | 1999-08-17 | Pharmaceutical compositions for oral and topical administration |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002106825/15A Division RU2279894C2 (ru) | 1999-08-17 | 2000-08-17 | Фармацевтические композиции для перорального и местного применения |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003133451A true RU2003133451A (ru) | 2005-04-20 |
| RU2279895C2 RU2279895C2 (ru) | 2006-07-20 |
Family
ID=10859192
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002106825/15A RU2279894C2 (ru) | 1999-08-17 | 2000-08-17 | Фармацевтические композиции для перорального и местного применения |
| RU2003133451/15A RU2279895C2 (ru) | 1999-08-17 | 2003-11-17 | Фармацевтические композиции для перорального и местного применения |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002106825/15A RU2279894C2 (ru) | 1999-08-17 | 2000-08-17 | Фармацевтические композиции для перорального и местного применения |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US20070190132A1 (ru) |
| EP (2) | EP1334717B1 (ru) |
| JP (2) | JP2003507343A (ru) |
| KR (2) | KR100828748B1 (ru) |
| CN (2) | CN101406453A (ru) |
| AR (2) | AR025324A1 (ru) |
| AT (2) | ATE288766T1 (ru) |
| AU (1) | AU777740B2 (ru) |
| BR (1) | BR0013385A (ru) |
| CA (2) | CA2452118A1 (ru) |
| CO (1) | CO5380014A1 (ru) |
| CY (1) | CY1105318T1 (ru) |
| CZ (2) | CZ296591B6 (ru) |
| DE (2) | DE60018081T2 (ru) |
| DK (2) | DK1210119T3 (ru) |
| EE (2) | EE04955B1 (ru) |
| EG (1) | EG23994A (ru) |
| ES (2) | ES2237443T3 (ru) |
| GB (1) | GB2355656B (ru) |
| HK (1) | HK1049629A1 (ru) |
| HR (1) | HRP20020154B1 (ru) |
| HU (1) | HUP0203236A3 (ru) |
| IL (4) | IL158108A0 (ru) |
| JO (1) | JO2324B1 (ru) |
| MX (1) | MXPA02001631A (ru) |
| NO (2) | NO20020760L (ru) |
| NZ (1) | NZ517271A (ru) |
| PE (1) | PE20010636A1 (ru) |
| PL (1) | PL192769B1 (ru) |
| PT (2) | PT1210119E (ru) |
| RU (2) | RU2279894C2 (ru) |
| SA (1) | SA00210487B1 (ru) |
| SG (1) | SG143019A1 (ru) |
| SI (1) | SI1210119T1 (ru) |
| SK (2) | SK2482002A3 (ru) |
| TN (1) | TNSN00173A1 (ru) |
| UA (2) | UA72539C2 (ru) |
| UY (1) | UY26303A1 (ru) |
| WO (1) | WO2001012229A1 (ru) |
| ZA (2) | ZA200308221B (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2355656B (en) * | 1999-08-17 | 2004-04-07 | Galena As | Pharmaceutical compositions for oral and topical administration |
| FR2826261B1 (fr) * | 2001-06-26 | 2005-03-25 | Lmd | Composition a usage topique comprenant un produit cytotoxique et son utilisation dans le traitement de l'alopeche |
| DE10154464B4 (de) * | 2001-11-08 | 2005-10-20 | Max Delbrueck Centrum | Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol |
| KR20030065831A (ko) * | 2002-02-01 | 2003-08-09 | 주식회사 태평양 | 사이클로스포린을 함유한 지속 방출형 약학적 조성물 |
| US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
| US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
| EP1935407A1 (en) * | 2002-12-03 | 2008-06-25 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
| WO2004050072A1 (ja) * | 2002-12-04 | 2004-06-17 | Nisshin Pharma Inc. | コエンザイムｑ１０を含有する水溶性組成物 |
| JP4518042B2 (ja) * | 2002-12-04 | 2010-08-04 | 日油株式会社 | コエンザイムｑ１０を含有する水溶性組成物の製造方法 |
| DK1585548T3 (en) * | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| US6979672B2 (en) | 2002-12-20 | 2005-12-27 | Polichem, S.A. | Cyclosporin-based pharmaceutical compositions |
| TW200616681A (en) * | 2004-10-05 | 2006-06-01 | Recordati Ireland Ltd | Lercanidipine capsules |
| EP1806125B1 (en) * | 2004-10-20 | 2011-08-03 | Kao Corporation | Liquid compositions for oral cavity |
| BRPI0608173A2 (pt) * | 2005-02-24 | 2010-11-09 | Elan Pharma Int Ltd | composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo |
| EP2364140A1 (en) * | 2008-11-28 | 2011-09-14 | Advance Holdings Limited | Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester |
| ES2403380T3 (es) * | 2009-03-12 | 2013-05-17 | Lectio Pharmaentwicklungs- Und Verwertungs Gmbh | Formulación farmacéutica que comprende cetoprofeno y un éster de polioxialquileno de un hidroxiácido graso |
| KR101100933B1 (ko) * | 2009-04-23 | 2012-01-02 | 한국기술교육대학교 산학협력단 | 솔더 볼 제거 장치 |
| KR20170131641A (ko) * | 2015-03-27 | 2017-11-29 | 아치 퍼스널 케어 프로덕츠, 엘.피. | 퍼스널 케어 제품용 점도 증강 조성물 |
| CN112426403B (zh) * | 2020-12-09 | 2021-09-17 | 南京天纵易康生物科技股份有限公司 | 一种口腔溃疡凝胶及其制备方法和应用 |
| WO2023214509A1 (ja) * | 2022-05-02 | 2023-11-09 | 中外製薬株式会社 | 界面活性剤と併用するためのペプチド化合物を含む組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0148748B1 (ko) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| US6007840A (en) * | 1988-09-16 | 1999-12-28 | Novartis Ag | Pharmaceutical compositions comprising cyclosporins |
| US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| CZ288631B6 (cs) * | 1996-01-18 | 2001-08-15 | Galena, A. S. | Léčivé přípravky s obsahem cyklosporinu |
| CZ288739B6 (cs) * | 1996-08-01 | 2001-08-15 | Galena, A. S. | Cyklosporin obsahující léčivé přípravky |
| CZ283516B6 (cs) * | 1996-09-12 | 1998-04-15 | Galena A.S. | Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů |
| CA2284000C (en) * | 1997-03-12 | 2012-01-03 | Abbott Laboratories | Hydrophilic binary systems for the administration of cyclosporine |
| CA2283780A1 (en) * | 1997-03-12 | 1998-09-17 | Abbott Laboratories | Lipophilic binary systems for the administration of lipophilic compounds |
| PT999826E (pt) * | 1997-07-29 | 2004-09-30 | Upjohn Co | Formulacao auto-emulsionante para compostos lipofilos |
| US6063762A (en) * | 1997-12-05 | 2000-05-16 | Chong Kun Dang Corp. | Cyclosporin-containing microemulsion preconcentrate composition |
| US20030216303A1 (en) * | 1998-03-06 | 2003-11-20 | Michael Ambuhl | Emulsion preconcentrates containing cyclosporin or a macrolide |
| GB2355656B (en) * | 1999-08-17 | 2004-04-07 | Galena As | Pharmaceutical compositions for oral and topical administration |
-
1999
- 1999-08-17 GB GB9919288A patent/GB2355656B/en not_active Revoked
-
2000
- 2000-08-17 AT AT00951765T patent/ATE288766T1/de active
- 2000-08-17 IL IL15810800A patent/IL158108A0/xx unknown
- 2000-08-17 PE PE2000000842A patent/PE20010636A1/es not_active Application Discontinuation
- 2000-08-17 CN CNA2008101094369A patent/CN101406453A/zh active Pending
- 2000-08-17 MX MXPA02001631A patent/MXPA02001631A/es active IP Right Grant
- 2000-08-17 AU AU64613/00A patent/AU777740B2/en not_active Ceased
- 2000-08-17 CN CN00813185A patent/CN1382061A/zh active Pending
- 2000-08-17 CZ CZ20032302A patent/CZ296591B6/cs not_active IP Right Cessation
- 2000-08-17 PT PT00951765T patent/PT1210119E/pt unknown
- 2000-08-17 PL PL353445A patent/PL192769B1/pl unknown
- 2000-08-17 HU HU0203236A patent/HUP0203236A3/hu unknown
- 2000-08-17 SI SI200030614T patent/SI1210119T1/xx unknown
- 2000-08-17 WO PCT/GB2000/003161 patent/WO2001012229A1/en not_active Ceased
- 2000-08-17 JP JP2001516572A patent/JP2003507343A/ja active Pending
- 2000-08-17 EE EEP200300371A patent/EE04955B1/xx not_active IP Right Cessation
- 2000-08-17 KR KR1020057015114A patent/KR100828748B1/ko not_active Expired - Fee Related
- 2000-08-17 BR BR0013385-0A patent/BR0013385A/pt not_active Application Discontinuation
- 2000-08-17 HR HR20020154A patent/HRP20020154B1/xx not_active IP Right Cessation
- 2000-08-17 RU RU2002106825/15A patent/RU2279894C2/ru not_active IP Right Cessation
- 2000-08-17 JO JO2000302A patent/JO2324B1/en active
- 2000-08-17 SG SG200305899-7A patent/SG143019A1/en unknown
- 2000-08-17 UY UY26303A patent/UY26303A1/es not_active Application Discontinuation
- 2000-08-17 ZA ZA200308221A patent/ZA200308221B/xx unknown
- 2000-08-17 CZ CZ20020575A patent/CZ296170B6/cs not_active IP Right Cessation
- 2000-08-17 AT AT03008447T patent/ATE402691T1/de active
- 2000-08-17 UA UA2002032078A patent/UA72539C2/uk unknown
- 2000-08-17 DK DK00951765T patent/DK1210119T3/da active
- 2000-08-17 CA CA002452118A patent/CA2452118A1/en not_active Abandoned
- 2000-08-17 CO CO00061955A patent/CO5380014A1/es not_active Application Discontinuation
- 2000-08-17 KR KR1020027002109A patent/KR100828747B1/ko not_active Expired - Fee Related
- 2000-08-17 DE DE60018081T patent/DE60018081T2/de not_active Expired - Lifetime
- 2000-08-17 EE EEP200200075A patent/EE04954B1/xx not_active IP Right Cessation
- 2000-08-17 SK SK248-2002A patent/SK2482002A3/sk unknown
- 2000-08-17 CA CA2380951A patent/CA2380951C/en not_active Expired - Fee Related
- 2000-08-17 HK HK03101840.7A patent/HK1049629A1/zh unknown
- 2000-08-17 ES ES00951765T patent/ES2237443T3/es not_active Expired - Lifetime
- 2000-08-17 TN TNTNSN00173A patent/TNSN00173A1/en unknown
- 2000-08-17 EP EP03008447A patent/EP1334717B1/en not_active Expired - Lifetime
- 2000-08-17 IL IL14820000A patent/IL148200A0/xx active IP Right Grant
- 2000-08-17 EP EP00951765A patent/EP1210119B1/en not_active Expired - Lifetime
- 2000-08-17 ES ES03008447T patent/ES2311077T3/es not_active Expired - Lifetime
- 2000-08-17 SK SK1023-2003A patent/SK286083B6/sk not_active IP Right Cessation
- 2000-08-17 DK DK03008447T patent/DK1334717T3/da active
- 2000-08-17 NZ NZ517271A patent/NZ517271A/en unknown
- 2000-08-18 AR ARP000104281A patent/AR025324A1/es unknown
- 2000-08-19 EG EG20001069A patent/EG23994A/xx active
- 2000-11-01 SA SA00210487A patent/SA00210487B1/ar unknown
-
2002
- 2002-02-15 NO NO20020760A patent/NO20020760L/no not_active Application Discontinuation
- 2002-02-15 ZA ZA200201315A patent/ZA200201315B/en unknown
- 2002-02-17 IL IL148200A patent/IL148200A/en not_active IP Right Cessation
- 2002-02-17 IL IL158108A patent/IL158108A/en not_active IP Right Cessation
-
2003
- 2003-04-26 PT PT03008447T patent/PT1334717E/pt unknown
- 2003-08-17 DE DE60322454T patent/DE60322454D1/de not_active Expired - Lifetime
- 2003-09-10 AR ARP030103268A patent/AR043106A2/es unknown
- 2003-10-24 NO NO20034778A patent/NO20034778D0/no not_active Application Discontinuation
- 2003-11-17 RU RU2003133451/15A patent/RU2279895C2/ru not_active IP Right Cessation
- 2003-12-24 UA UA20031212327A patent/UA75926C2/uk unknown
-
2004
- 2004-03-31 JP JP2004106963A patent/JP2004238399A/ja active Pending
-
2005
- 2005-05-05 CY CY20051100574T patent/CY1105318T1/el unknown
-
2007
- 2007-04-13 US US11/786,846 patent/US20070190132A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003133451A (ru) | Фармацевтические композици для перорального и местного применения | |
| RU2002106825A (ru) | Фармацевтические композиции для перорального и местного применения | |
| JP3420897B2 (ja) | 医薬組成物 | |
| KR0167696B1 (ko) | 사이클로스포린-함유 연질캅셀제 조성물 | |
| EP0710103B1 (de) | Pharmazeutische präparate für schwerlösliche wirkstoffe | |
| DE60019100T2 (de) | Im wesentlichen ölfreie cyclosporin zusammensetzungen | |
| KR100587551B1 (ko) | 오메가-3 지방산 오일을 함유하는 약학 조성물 | |
| AT400518B (de) | Nagellack zur behandlung von onychomykosis enthaltend terbinafine | |
| TWI240636B (en) | Spontaneously dispersible pharmaceutical containing n-benzoyl-staurosporine and the use thereof | |
| RU96102012A (ru) | Фармацевтический состав для солюбилизации плохо растворимого активного агента в составе-носителе и способ его изготовления | |
| KR870009720A (ko) | 서방형 신규 제약 제제물 | |
| EP1109532A1 (en) | Oral micro-emulsion composition of silybin | |
| LV11885B (en) | Medical preparations containing n-methylated cyclic undecapeptides | |
| EP0063870A2 (en) | Cream preparation | |
| JP3862273B2 (ja) | 経口投与用シクロスポリン含有新規製剤 | |
| JP2006501208A (ja) | 経口投与用シクロスポリン、プロピレングリコールエステルおよび非イオン性界面活性剤含有医薬組成物。 | |
| JPS6321648B2 (ru) | ||
| JP2004043511A (ja) | サイクロスポリン含有軟質カプセル製剤 | |
| JP2003503339A (ja) | 抗癌剤を含有する自己乳化システム | |
| JP4139909B2 (ja) | ソフトカプセル用基剤 | |
| JP3748912B2 (ja) | オーレオバシジン類の高濃度溶液製剤 | |
| WO1997004795A2 (en) | Pharmaceutical compositions containing cyclosporin or other peptide substances | |
| JPS56166108A (en) | Base for cosmetic and medicine | |
| RU2000128205A (ru) | Фармацевтическая композиция, включающая циклоспорин в качестве активного ингредиента | |
| WO1995021624A1 (en) | High-concentration aureobasidin preparation in solution form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner | ||
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20070818 |